Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 2, 2024Open Access

Regulatory Role of IL-6 in Immune-Related Adverse Events During Checkpoint Inhibitor Treatment in Melanoma

View Full Paper
Ask AI
Bookmark
Share

Authors

KSKrishna P. SinghASAnuj SinghOWOlaf Wolkenhauer

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Singh et al. (2024) studied this question.

synapsesocial.com/papers/68e59a2bb6db643587534f12https://doi.org/10.20944/preprints202409.0006.v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Regulatory Role of IL6 in Immune-Related Adverse Events during Checkpoint Inhibitor Treatment in Melanoma2024
  2. 2Comprehensive Assessment of Prognostic Factors for Immune-Related Adverse Events in Immune Checkpoint Inhibitor-Treated Melanoma2025 · 3 citations
  3. 3Immune phenotype modulation in peripheral T and B cells after immune checkpoint inhibitor therapy in melanoma 27262025
  4. 4Immune-Related Adverse Events Due to Cancer Immunotherapy: Immune Mechanisms and Clinical Manifestations2024 · 83 citations
  5. 5Prophylactic IL-23 blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy2024 · 26 citations